Estrogen Patch for COVID-19 Symptoms
Clara Health

Estrogen Patch for COVID-19 Symptoms

Sponsored by Stony Brook University

As the COVID19 pandemic has spread, it has been observed that adult men of all ages and older women are at higher risk of developing serious complications from infection with the virus. Animal model studies of SARS suggest that the age and sex difference in COVID19 symptom severity may be due to protective and acute actions of the female sex hormone estrogen. Animal and human studies support immune modulating effects of estrogen that are acute acting in viral infections and wound repair processes that may reduce the damaging effects of the virus on the lung and symptom severity.

The purpose of this study is to find out if estrogen, a female sex hormone, given as a patch placed on skin of COVID19 positive or presumptive positive patients for 7 days can reduce the severity of COVID19 symptoms compared to regular care.


Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

This study has two study groups. One group will receive the study drug, a single-use Climara 25cm2 estrogen patch. The other group will receive standard of care.

Study type: Interventional (Clinical Trial) Estimated Enrollment: 110 participants Official Title: Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients Actual Study Start Date: April 20, 2020 Estimated Study Completion Date: November 15, 2020

Who is this study for?

Inclusion Criteria*:

  • Male ≥ 18 years of age or female ≥ 55 years of age
  • Documentation of COVID19 positivity or the presence of one or more of the following new onset (<7 days) clinical features defining presumptive COVID19
    • fever of >100.5°F or 38°C
    • shortness of breath
    • cough
    • radiologic evidence of pneumonia

* Additional criteria apply. Please speak with the study team for further information.

What should I expect?

Drug: Estradiol patch Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin

Participants will be asked questions about their symptoms for up 6 times in up to 45 days.

Have a question?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.